CDTX - Cidara rallies 13% after hours on UK approval for Rezzayo
2024-01-29 17:12:24 ET
More on Cidara Therapeutics, Halozyme Therapeutics, etc.
- Halozyme Therapeutics: A Reasonable Value In An Overvalued Market
- Halozyme Q3: Navigating The Ups And Downs Of Its Innovative Pathway
- Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings Call Transcript
- Halozyme’s early 2023 results indicate a mixed performance
- Halozyme gains as U.S. and EU clear Enhanze-based products